Followers | 438 |
Posts | 45331 |
Boards Moderated | 4 |
Alias Born | 05/11/2008 |
Sunday, August 15, 2021 5:55:09 AM
https://temertymedicine.utoronto.ca/news/u-t-test-new-drug-covid-19-edesa-biotech
Impressive read about .DR. PAR NIJHAWAN
Dr. Par Nijhawan is a seasoned physician and entrepreneur with 20 years of experience in cross-functional roles including finance, marketing and business and drug development. Dr. Nijhawan is the Founder and CEO of Edesa Biotech. In addition, he is the Founder and Chairman of Exzell Pharma, ranked as Canada’s fastest growing company in 2019. Dr. Nijhawan was Founder and CEO of Medical Futures Inc., a specialty pharmaceutical company which he successfully sold to a public company in 2015. He also established Digestive Health Clinic, Canada’s largest provider of private endoscopy services. Dr. Nijhawan was inducted into the CHLA BD Hall of fame in 2018 and Awarded Business Development Deal of the Year 2017. Dr. Nijhawan received his MD (University of Ottawa), Internship (Yale), Residency IM (Mayo), Fellowship GI (Mayo)
https://www.prnewswire.com/news-releases/edesa-biotech-wins-chla-award-for-best-bd-deal-of-2017-and-dr-par-nijhawan-inducted-into-the-chla-hall-of-fame-675970213.html
Recent EDSA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 11:20:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2024 09:46:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:20:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:30:45 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/29/2024 09:29:02 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/16/2024 10:03:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:30:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/15/2023 09:44:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:17:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:01:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 11:58:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 04:22:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 12:01:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:33:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:22:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/04/2023 08:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/04/2023 08:18:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/04/2023 08:18:55 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 07/24/2023 08:56:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM